Advertisement

Bladder Cancer Screening—Systematic Review Results

  • Sanchia S. GoonewardeneEmail author
  • Raj Persad
  • Hanif Motiwala
  • David Albala
Chapter

Abstract

Bladder cancer is a malignancy that affects mainly the elderly and males (Rybotycka and Długosz in Pol Merkur Lekarski 38(228):309, 2015). Up to 90% of these cancers originate from urothelial epithelial cells (Rybotycka and Długosz in Pol Merkur Lekarski 38(228):309, 2015). This chapter deals with the systematic review results on screening in bladder cancer.

References

  1. Abdollahzadeh P, Madani SH, Khazaei S, Sajadimajd S, Izadi B, Najafi F. Association between human papillomavirus and transitional cell carcinoma of the bladder. Urol J. 2017;14(6):5047–50.Google Scholar
  2. Allione A, Pardini B, Viberti C, Giribaldi G, Turini S, Di Gaetano C, Guarrera S, Cordero F, Oderda M, Allasia M, Gontero P, Sacerdote C, Vineis P, Matullo G. MMP23B expression and protein levels in blood and urine are associated with bladder cancer. Carcinogenesis. 2018.Google Scholar
  3. Bangma CH, Loeb S, Busstra M, Zhu X, El Bouazzaoui S, Refos J, Van Der Keur KA, Tjin S, Franken CG, van Leenders GJ, Zwarthoff EC, Roobol MJ. Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers. Eur Urol. 2013;64(1):41–7.PubMedCrossRefGoogle Scholar
  4. Behrens A, Stehle T, Gross S, Aach T. Local and global panoramic imaging for fluorescence bladder endoscopy. In: Conference Proceedings of the IEEE Engineering in Medicine and Biology Society. 2009. p. 6990–3.Google Scholar
  5. Bonberg N, Taeger D, Gawrych K, Johnen G, Banek S, Schwentner C, Sievert KD, Wellhäußer H, Kluckert M, Leng G, Nasterlack M, Stenzl A, Behrens T, Brüning T, Pesch B; UroScreen Study Group. Chromosomal instability and bladder cancer: the UroVysion(TM) test in the UroScreen study. BJU Int. 2013;112(4):E372–82.PubMedPubMedCentralCrossRefGoogle Scholar
  6. Böthig R, Fiebag K, Kowald B, Hirschfeld S, Thietje R, Kurze I, Schöps W, Böhme H, Kaufmann A, Zellner M, Kadhum T, Golka K. Spinal cord injury with neurogenic lower urinary tract dysfunction as a potential risk factor for bladder carcinoma. Aktuelle Urol. 2018.Google Scholar
  7. Carreón T, Hein MJ, Hanley KW, Viet SM, Ruder AM. Bladder cancer incidence among workers exposed to o-toluidine, aniline and nitrobenzene at a rubber chemical manufacturing plant. Occup Environ Med. 2014;71(3):175–82.PubMedPubMedCentralCrossRefGoogle Scholar
  8. Cassidy LD, Marsh GM, Talbott EO, Kelsey SFInitial and continued adherence with bladder cancer screening in an occupationally exposed cohort. J Occup Environ Med. 2011;53(4):455–6.Google Scholar
  9. Chavan S, Bray F, Lortet-Tieulent J, Goodman M, Jemal A. International variations in bladder cancer incidence and mortality. Eur Urol. 2014;66(1):59–73.  https://doi.org/10.1016/j.eururo.2013.10.001.CrossRefPubMedPubMedCentralGoogle Scholar
  10. Chou R, Dana T. Screening adults for bladder cancer: a review of the evidence for the U.S. preventive services task force. Ann Intern Med. 2010;153(7):461–8.PubMedPubMedCentralCrossRefGoogle Scholar
  11. Cicione A, Manno S, Ucciero G, Cantiello F, Damiano R, Lima E, Posti A, Balloni F, De Nunzio C. A larger detrusor wall thickness increases the risk of non muscle invasive bladder cancer recurrence and progression: result from a multicenter observational study. Minerva Urol Nefrol. 2018;70(3):310–18.Google Scholar
  12. Daneshmand S, Schuckman AK, Bochner BH, Cookson MS, Downs TM, Gomella LG, Grossman HB, Kamat AM, Konety BR, Lee CT, Pohar KS, Pruthi RS, Resnick MJ, Smith ND, Witjes JA, Schoenberg MP, Steinberg GD. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA 2014.Google Scholar
  13. Daniely M, Rona R, Kaplan T, Olsfanger S, Elboim L, Freiberger A, Lew S, Leibovitch I. Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology. Cancer. 2007;111(6):517–24.PubMedCrossRefGoogle Scholar
  14. Drejer D, Béji S, Munk Nielsen A, Høyer S, Wrist Lam G, Jensen JB. Clinical relevance of narrow-band imaging in flexible cystoscopy: the DaBlaCa-7 study. Scand J Urol. 2017;51(2):120–123.PubMedCrossRefGoogle Scholar
  15. Eifler JB, Barocas DA, Resnick MJ. Predictors of outcome in bladder cancer. J Natl Compr Canc Netw. 2014;12(11):1549–54.PubMedCrossRefGoogle Scholar
  16. Ellwein LB, Farrow GM. Urinary cytology screening: the decision facing the asymptomatic patient. Med Decis Making. 1988;8(2):110–9.PubMedCrossRefGoogle Scholar
  17. Fernandez CA, Millholland JM, Zwarthoff EC, Feldman AS, Karnes RJ, Shuber AP. A noninvasive multi-analyte diagnostic assay: combining protein and DNA markers to stratify bladder cancer patients. Res Rep Urol. 2012;4:17–2.Google Scholar
  18. Ferris J, Garcia J, Berbel O, Ortega JA. Constitutional and occupational risk factors associated with bladder cancer. Actas Urol Esp. 2013;37(8):513–22.CrossRefGoogle Scholar
  19. Freitas NR, Vieira PM, Lima E, Lima CS. Automatic T1 bladder tumor detection by using wavelet analysis in cystoscopy images. Phys Med Biol. 2018;63(3):035031.CrossRefGoogle Scholar
  20. Gharibvand MM, Kazemi M, Motamedfar A, Sametzadeh M, Sahraeizadeh A. The role of ultrasound in diagnosis and evaluation of bladder tumors. J Family Med Prim Care. 2017;6(4):840–43.PubMedPubMedCentralCrossRefGoogle Scholar
  21. Grotenhuis AJ, Ebben CW, Aben KK, Witjes JA, Vrieling A, Vermeulen SH, Kiemeney LA. The effect of smoking and timing of smoking cessation on clinical outcome in non-muscle-invasive bladder cancer. Urol Oncol. 2015;33(2):65.e9–17.CrossRefGoogle Scholar
  22. Guillaume L, Guy L. Epidemiology of and risk factors for bladder cancer and for urothelial tumors. Rev Prat. 2014;64(10):1372–4, 1378–80.Google Scholar
  23. Horstmann M, Banek S, Gakis G, Todenhöfer T, Aufderklamm S, Hennenlotter J, Stenzl A, Schwentner C. UroScreen study group. Prospective evaluation of fluorescence-guided cystoscopy to detect bladder cancer in a high-risk population: results from the UroScreen-Study. Springerplus. 2014;3:24.PubMedPubMedCentralCrossRefGoogle Scholar
  24. Houskova L, Zemanova Z, Babjuk M, Melichercikova J, Pesl M, Michalova K. Molecular cytogenetic characterization and diagnostics of bladder cancer. Neoplasma. 2007;54(6):511–6.Google Scholar
  25. Inoue K, Ota U, Ishizuka M, Kawada C, Fukuhara H, Shuin T, Okura I, Tanaka T, Ogura S. Porphyrins as urinary biomarkers for bladder cancer after 5-aminolevulinic acid (ALA) administration: the potential of photodynamic screening for tumors. Photodiagnosis Photodyn Ther. 2013;10(4):484–9.PubMedCrossRefGoogle Scholar
  26. Jochems SHJ, van Osch FHM, Reulen RC, van Hensbergen M, Nekeman D, Pirrie S, Wesselius A, van Schooten FJ, James ND, Wallace DMA, Bryan RT, Cheng KK, Zeegers MP. Fruit and vegetable intake and the risk of recurrence in patients with non-muscle invasive bladder cancer: a prospective cohort study. Cancer Causes Control. 2018;29(6):573–79.CrossRefGoogle Scholar
  27. Johnen G, Gawrych K, Bontrup H, Pesch B, Taeger D, Banek S, Kluckert M, Wellhäußer H, Eberle F, Nasterlack M, Leng G, Stenzl A, Brüning T; UroScreen Study Group. Performance of survivin mRNA as a biomarker for bladder cancer in the prospective study UroScreen. PLoS One. 2012;7(4):e35363.  https://doi.org/10.1371/journal.pone.0035363. Epub 2012 Apr 16.PubMedPubMedCentralCrossRefGoogle Scholar
  28. Kenney DM, Geschwindt RD, Kary MR, Linic JM, Sardesai NY, Li ZQ. Detection of newly diagnosed bladder cancer, bladder cancer recurrence and bladder cancer in patients with hematuria using quantitative rt-PCR of urinary survivin. Tumour Biol. 2007;28(2):57–62.PubMedCrossRefGoogle Scholar
  29. Kollarik B, Zvarik M, Bujdak P, Weibl P, Rybar L, Sikurova L, Hunakova L. Urinary fluorescence analysis in diagnosis of bladder cancer. Neoplasma. 2018;65(2):234–41.PubMedCrossRefGoogle Scholar
  30. Larré S, Catto JW, Cookson MS, Messing EM, Shariat SF, Soloway MS, Svatek RS, Lotan Y, Zlotta AR, Grossman HB. Screening for bladder cancer: rationale, limitations, whom to target, and perspective. Eur Urol. 2013;63(6):1049–58.PubMedPubMedCentralCrossRefGoogle Scholar
  31. Letašiová S, Medve’ová A, Šovčíková A, Dušinská M, Volkovová K, Mosoiu C, Bartonová A. Bladder cancer, a review of the environmental risk factors. Environ Health. 2012;11(Suppl. 1):S11.PubMedPubMedCentralCrossRefGoogle Scholar
  32. Li S, Li L, Zeng Q, Zhang Y, Guo Z, Liu Z, Jin M, Su C, Lin L, Xu J, Liu S. Characterization and noninvasive diagnosis of bladder cancer with serum surface enhanced Raman spectroscopy and genetic algorithms. Sci Rep. 2015;5:9582.Google Scholar
  33. Liang LG, Sheng YF, Zhou S, Inci F, Li L, Demirci U, Wang S. An integrated double-filtration microfluidic device for detection of extracellular vesicles from urine for bladder cancer diagnosis. Methods Mol Biol. 2017;1660:355–64.PubMedCrossRefGoogle Scholar
  34. Llewellyn MA, Gordon NS, Abbotts B, James ND, Zeegers MP, Cheng KK, Macdonald A, Roberts S, Parish JL, Ward DG, Bryan RT. Defining the frequency of human papillomavirus and polyomavirus infection in urothelial bladder tumours. Sci Rep. 2018;8(1):11290.Google Scholar
  35. Maas M, Walz S, Stühler V, Aufderklamm S, Rausch S, Bedke J, Stenzl A, Todenhöfer T. Molecular markers in disease detection and follow-up of patients with non-muscle invasive bladder cancer. Expert Rev Mol Diagn. 2018;18(5):443–55.PubMedCrossRefGoogle Scholar
  36. Mäkelä VJ, Kotsar A, Tammela TL, Murtola TJ. Bladder cancer survival in men using 5-alpha-reductase inhibitors. J Urol. 2018;(18)43085–6. pii:S0022–5347.Google Scholar
  37. Malats N, Real FX. Epidemiology of bladder cancer. Hematol Oncol Clin North Am. 2015;29(2):177–89, vii.PubMedPubMedCentralCrossRefGoogle Scholar
  38. Martini T, Mayr R, Lodde M, Seitz C, Trenti E, Comploj E, Palermo S, Pycha A, Mian C, Zywica M, Weidner W, Lüdecke G. Validation of RiskCheck Bladder Cancer©, version 5.0 for risk-adapted screening of bladder cancer. Urol Int. 2013;91(2):175–81.PubMedPubMedCentralCrossRefGoogle Scholar
  39. Messing EM, Madeb R, Young T, Gilchrist KW, Bram L, Greenberg EB, Wegenke JD, et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer. 2006;107(9):2173–9.PubMedCrossRefGoogle Scholar
  40. Orywal K, Jelski W, Werel T, Szmitkowski M. The diagnostic significance of serum alcohol dehydrogenase isoenzymes and aldehyde dehydrogenase activity in urinary bladder cancer patients. Anticancer Res. 2017;37(7):3537–41.PubMedPubMedCentralGoogle Scholar
  41. Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract. 2002;10(6):311–22.PubMedPubMedCentralCrossRefGoogle Scholar
  42. Pedersen M, Stafoggia M, Weinmayr G, Andersen ZJ, Galassi C, Sommar J, Forsberg B, Olsson D, Oftedal B, Krog NH, Aamodt G, Pyko A, Pershagen G, Korek M, De Faire U, Pedersen NL, Östenson CG, Fratiglioni L, Sørensen M, Eriksen KT, Tjønneland A, Peeters PH, Bueno-de-Mesquita B, Vermeulen R, Eeftens M, Plusquin M, Key TJ, Jaensch A, Nagel G, Concin H, Wang M, Tsai MY, Grioni S, Marcon A, Krogh V, Ricceri F, Sacerdote C, Ranzi A, Cesaroni G, Forastiere F, Tamayo I, Amiano P, Dorronsoro M, Stayner LT, Kogevinas M, Nieuwenhuijsen MJ, Sokhi R, de Hoogh K, Beelen R, Vineis P, Brunekreef B, Hoek G, Raaschou-Nielsen O. Is there an association between ambient air pollution and bladder cancer incidence? Analysis of 15 European Cohorts. Eur Urol Focus. 2018;4(1):113–20.PubMedCrossRefGoogle Scholar
  43. Pesch B, Nasterlack M, Eberle F, Bonberg N, Taeger D, Leng G, Feil G, Johnen G, Ickstadt K, Kluckert M, Wellhäusser H, Stenzl A, Brüning T; UroScreen Group. The role of haematuria in bladder cancer screening among men with former occupational exposure to aromatic amines. BJU Int. 2011;108(4):546–52.Google Scholar
  44. Pospisilova S, Pazourkova E, Horinek A, Brisuda A, Svobodova I, Soukup V, Hrbacek J, Capoun O, Hanus T, Mares J, Korabecna M, Babjuk M. MicroRNAs in urine supernatant as potential non-invasive markers for bladder cancer detection. Neoplasma. 2016;63(5):799–808.PubMedCrossRefGoogle Scholar
  45. Ratert N, Meyer HA, Jung M, Lioudmer P, Mollenkopf HJ, Wagner I, Miller K, Kilic E, Erbersdobler A, Weikert S, Jung K. miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. J Mol Diagn. 2013;15(5):695–705.PubMedCrossRefGoogle Scholar
  46. Rybotycka Z, Długosz A. Diagnostic significance of protein NMP22 in bladder cancer. Pol Merkur Lekarski. 2015;38(228):309.PubMedGoogle Scholar
  47. Sanchini MA, Gunelli R, Nanni O, Bravaccini S, Fabbri C, Sermasi A, Bercovich E, Ravaioli A, Amadori D, Calistri D. Relevance of urine telomerase in the diagnosis of bladder cancer. JAMA. 2005.Google Scholar
  48. Schiffer E, Vlahou A, Petrolekas A, Stravodimos K, Tauber R, Geschwend JE, Neuhaus J, Stolzenburg JU, Conaway MR, Mischak H, Theodorescu D. Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin Cancer Res. 2009;15(15):4935–43.PubMedCrossRefGoogle Scholar
  49. Schmitz-Dräger BJ, Droller M, Lokeshwar VB, Lotan Y, Hudson MA, van Rhijn BW, Marberger MJ, Fradet Y, Hemstreet GP, Malmstrom PU, Ogawa O, Karakiewicz PI, Shariat SF. Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus. Urol Int. 2015;94(1):1–24.PubMedCrossRefGoogle Scholar
  50. Schmitz-Dräger BJ, Todenhöfer T, van Rhijn B, Pesch B, Hudson MA, Chandra A, Ingersoll MA, Kassouf W, Palou J, Taylor J, Vlahou A, Behrens T, Critelli R, Grossman HB, Sanchez-Carbayo M, Kamat A. Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer. Urol Oncol. 2014;32(7):1061–8.PubMedCrossRefGoogle Scholar
  51. Shimizu Y, Furuya H, Bryant Greenwood P, Chan O, Dai Y, Thornquist MD, Goodison S, Rosser CJ. A multiplex immunoassay for the non-invasive detection of bladder cancer. J Transl Med. 2016;14:31.Google Scholar
  52. Simonis K, Shariat SF, Rink M. Smoking and smoking cessation effects on oncological outcomes in nonmuscle invasive bladder cancer. Curr Opin Urol. 2014;24(5):492–9.PubMedPubMedCentralCrossRefGoogle Scholar
  53. Soukup V, Kalousová M, Capoun O, Sobotka R, Breyl Z, Pešl M, Zima T, Hanuš T. Panel of urinary diagnostic markers for non-invasive detection of primary and recurrent urothelial urinary bladder carcinoma. Urol Int. 2015;95(1):56–64.PubMedCrossRefGoogle Scholar
  54. Starke N, Singla N, Haddad A, Lotan Y. Long-term outcomes in a high-risk bladder cancer screening cohort. BJU Int. 2016;117(4):611–9.PubMedCrossRefGoogle Scholar
  55. Szygula M, Wojciechowski B, Adamek M, Pietrusa A, Kawczyk-Krupka A, Cebula W, Zieleznik W, Biniszkiewicz T, Duda W, Sieroń A. Fluorescent diagnosis of urinary bladder cancer-a comparison of two diagnostic modalities. Photodiagnosis Photodyn Ther. 2004;1(1):23–6.PubMedCrossRefGoogle Scholar
  56. Tan WS, Rodney S, Lamb B, Feneley M, Kelly J. Management of non muscle invasive bladder cancer: a comprehensive analysis of guidelines from the United States, Europe and Asia. Cancer Treat Rev. 2016;47:22–31.PubMedCrossRefGoogle Scholar
  57. Teleka S, Häggström C, Nagel G, Bjørge T, Manjer J, Ulmer H, Liedberg F, Ghaderi S, Lang A, Jonsson H, Jahnson S, Orho-Melander M, Tretli S, Stattin P, Stocks T. Risk of bladder cancer by disease severity in relation to metabolic factors and smoking; a prospective pooled cohort study of 800,000 men and women. Int J Cancer. 2018.Google Scholar
  58. Turco P, Houssami N, Bulgaresi P, Troni GM, Galanti L, Cariaggi MP, Cifarelli P, Crocetti E, Ciatto S. Is conventional urinary cytology still reliable for diagnosis of primary bladder carcinoma? Accuracy based on data linkage of a consecutive clinical series and cancer registry. Acta Cytol. 2011;55(2):193–6.PubMedCrossRefGoogle Scholar
  59. van Osch FHM, Jochems SHJ, Reulen RC, Pirrie SJ, Nekeman D, Wesselius A, James ND, et al. The association between smoking cessation before and after diagnosis and non muscle-invasive bladder cancer recurrence: a prospective cohort study. Cancer Causes Control. 2018;29(7):675–83.CrossRefGoogle Scholar
  60. Vickers AJ, Bennette C, Kibel AS, Black A, Izmirlian G, Stephenson AJ, Bochner B. Who should be included in a clinical trial of screening for bladder cancer? A decision analysis of data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Cancer. 2013;119(1):143–9.PubMedPubMedCentralCrossRefGoogle Scholar
  61. Wach S, Weigelt K, Michalke B, Lieb V, Stoehr R, Keck B, Hartmann A, et al. Diagnostic potential of major and trace elements in the serum of bladder cancer patients. J Trace Elem Med Biol. 2018;46:150–55.PubMedCrossRefPubMedCentralGoogle Scholar
  62. Whelan P, Britton JP, Dowell AC. Three-year follow-up of bladder tumours found on screening. Br J Urol. 1993;72(6):893–6.PubMedCrossRefPubMedCentralGoogle Scholar
  63. Xylinas E, Kluth LA, Rieken M, Karakiewicz PI, Lotan Y, Shariat SF. Urine markers for detection and surveillance of bladder cancer. Urol Oncol. 2014;32(3):222–9.PubMedCrossRefPubMedCentralGoogle Scholar
  64. Yeung C, Dinh T, Lee J. The health economics of bladder cancer: an updated review of the published literature. Pharmacoeconomics. 2014;32(11):1093–104.PubMedPubMedCentralCrossRefGoogle Scholar
  65. Zlotta AR, Roumeguere T, Kuk C, Alkhateeb S, Rorive S, Lemy A, van der Kwast TH, Fleshner NE, Jewett MA, Finelli A, Schulman C, Lotan Y, Shariat SF, Nortier J. Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer. Eur Urol. 2011;59(6):1026–31.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Sanchia S. Goonewardene
    • 1
    Email author
  • Raj Persad
    • 2
  • Hanif Motiwala
    • 3
  • David Albala
    • 4
  1. 1.East of England DeaneryNorfolk and Norwich University HospitalNorwichUK
  2. 2.North Bristol NHS TrustBristolUK
  3. 3.Southend University HospitalWestcliff-on-SeaUK
  4. 4.Boston UniversityBostonUSA

Personalised recommendations